Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Intersect Ent.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Intersect Ent.

Regulatory records
3
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 3 FDA records to the applicant name Intersect Ent.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 11, 2011 to Sep 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code OWO appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P100044, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 1555 Adams Dr., Menlo Park, CA, 94025. Recorded on P100044/S060, decision dated Sep 23, 2026.

Changes described in PMA records

P100044/S060: Propel Family Products

The FDA recorded an approval dated 2026-09-23 for supplement P100044/S060, submitted by Intersect Ent. under the Propel Family Products. The supplement's stated purpose is a shelf-life extension from 24 months to 36 months, filed as a real-time process supplement with the reason given as a labeling change covering indications, instructions, shelf life or tradename. The product category listed is a drug-eluting sinus stent in the ear, nose and throat specialty, product code OWO.

That approval modifies the terms of the existing P100044 PMA; it is not a new approval of the whole system. The database does not state what evidence supported the extension, what the stent's original indications were, or what labeling text changed, so those details remain unknown. The source statement reports a purpose set by the applicant, which does not by itself establish safety or clinical effectiveness.

FDA approval-order wording

Approval for a shelf-life extension of the Propel Family Products from 24 months to 36 months

Sep 23, 2026 · Real-Time Process

P100044/S061: PROPEL

The FDA record P100044/S061, dated 2026-09-22, is a 30-Day Notice supplement to PMA P100044 for the Propel Product Family, an OWO drug-eluting sinus stent from Intersect Ent. in the ear, nose, and throat specialty. Its supplement reason is listed as Process Change - Manufacturer/Sterilizer/Packager/Supplier, with the decision recorded as OK30.

The stated change is approval to implement an automated vision sensor for inspection of correct or incorrect packaging orientation when the product is placed in a shipper. This describes an inspection step tied to packaging orientation in shipping configuration; the record does not identify sensor make, detection method, acceptance criteria, or validation data, and the statement's purpose is not independent proof of safety or clinical effectiveness.

FDA approval-order wording

approval to implement an automated vision sensor for inspection of correct or incorrect packaging orientation for the Propel Product Family when placed in a shipper

Sep 22, 2026 · 30-Day Notice

P100044: PROPEL

The FDA approved the PROPEL sinus implant for patients 18 years and older after ethmoid sinus surgery. The stated purpose is to maintain patency and reduce the need for post-operative intervention such as surgical adhesion lysis or oral steroid use.

The device is described as separating mucosal tissues, stabilizing the middle turbinate, preventing obstruction by adhesions, and reducing edema. The source statement reports these intended functions but does not provide independent proof of safety or clinical effectiveness. No supplement type or reason is recorded.

FDA approval-order wording

APPROVAL FOR THE PROPEL SINUS IMPLANT. THIS DEVICE IS INDICATED FOR USE IN PATIENTS >= 18 YEARS OF AGE FOLLOWING ETHMOID SINUS SURGERY TO MAINTAIN PATENCY, THEREBY REDUCING THE NEED FOR POST-OPERATIVE INTERVENTION SUCH AS SURGICAL ADHESION LYSIS AND/OR USE OF ORAL STEROIDS. THE PROPEL SINUS IMPLANT SEPARATES MUCOSAL TISSUES, PROVIDES STABILIZATION OF THE MIDDLE TURBINATE, PREVENTS OBSTRUCTION BY ADHESIONS, AND REDUCES EDEMA.

Aug 11, 2011

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Intersect Ent.PMA supplementSep 23, 2026FDA
PROPELP100044/S061
Intersect Ent.PMA supplementSep 22, 2026FDA
PROPELP100044
Intersect Ent.PMA approvalAug 11, 2011FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.